## **Negative Pressure Wound Therapy Referral Information Sheet**

	legative Pressure Wo n must complete the f			ician /
Date:		Address:		
Client Name:		_		
BRN:		_		
Date of Birth (d/mm/yy	/yy):			
Comprehensive holistic	patient and wound ass	essment completed. P	atient is appropriate fo	or use of
Wound Type: Diagnosis	s (Check one):			
☐ Pilonidal sinuses ☐ Pressure Injuries ☐	☐ Large surgical wound ☐ Orthopedic wound	<ul><li>☐ Mediastinal wound</li><li>☐ Traumatic wounds</li></ul>	<ul><li>□ Necrotizing fasci</li><li>□ Diabetic foot</li></ul>	itis wounds
☐ Other:				
Wound Location:				_
Wound measurements & d	description: Length:	cm x width:	_cm x Depth:	_cm
Undermining:		Tunneling:		
9 3		1:	3	
6		6		
Expected therapy goals	: (i.e. Flap/Graft/Closure/Pre	ep for Surgery)		
		in	_weeks.	

## Wounds must meet the following criteria to be eligible for NPWT therapy:

- Open wounds for secondary closure or dehisced incision lines (typically changed every 42-78 hours)
- Closed Incisional support (can be left in place 2-7 days)
- Skin graft bolstering (left in place 4-5 days and removed by surgeon)
- Wound is well perfused
- Wound has a healthy wound bed with no greater than 20% necrotic tissue present
- Client's overall clinical condition is optimized

NPWT contraindications and precautions			
Inadequately debrided wound with presence of necrotic tissue (greater than 20% of wound bed)	No sharp fragments of bone are present in the wound.		
Nutritional status is not adequate to support healing. (e.g. Braden nutritional score < 3, Nutritional compromise with serum albumin <35 g/dl, or prealbumin level <16 mg/dL.)	Exposed tendons, ligaments and nerves must be protected with meshed non-adherent dressings or white foam before the NPWT dressing is applied.		
Severe excoriation of periwound skin.	Client receiving anticoagulants with stable INRs.		
An unexplored fistula or tunnel to organs or body cavities (other than chronic enteric fistulas.)	Not experiencing active bleeding or anemia		
Unresolved, untreated osteomyelitis and any infection that is untreated prior to application.	Immunodeficient disease (e.g.Leukemia, HIV), haematologic disorders, diabetes and/or hypertension are		
that is unificated prior to application.	well controlled.		
Malignancy or cancer in wound margins.	No current abuse of drugs or alcohol.		
Unresolved bleeding following debridement.	Systemic steroids.		
Exposed blood vessels and/or organs	Inflammatory ulcers (e.g. pyoderma, vasculitis)		
Client experiencing difficult homeostasis after	Insufficient ability to maintain an airtight seal due to		
debridement.	location of the wound, incision or skin graft.		

HOME AND COMMUNITY CARE SUPPORT SERVICES SOUTH WEST

## **Negative Pressure Wound Therapy Referral Information Sheet**

## **Discontinuation Criteria:**

- When there is no measurable progress to wound healing within two weeks;
- When there is not 20-40 percent reduction in the size of the wound within three to four weeks;
- The wound has healed such that the foam no longer fits the wound;
- The goals for healing have been met;
- If any of the following occur: bleeding, bruising, unmanaged pain in response to the therapy, an occlusive seal cannot be achieved, the client does not comply with the treatment regime, or the wound deteriorates.
- Regardless of decrease in size, if the wound is healing as expected the NPWT will be discontinued by the end of 6 to 8 weeks of treatment

The MRP or ordering	g health care provider has as	ssessed that N	IPWT is safe	to use for this clier	nt:YES	NO
NPWT TREATMI	ENT PLAN – Identify tre	atment typ	oe, dressin	g type, size, ar	nd delivery requ	ired:
KCI ActiVAC:	☐ Granufoam Kit: ☐ Whitefoam Kit:	☐ Small	☐ Medium	☐ Large		
	☐ 300 ml Cannister	Li Siliali	□ Large			
Initial Settings :	☐ Continuous (1st 48 hours	s all wounds)		☐ Intermitte	nt (if wound appropria	te, after 48 hrs)
□ 25mm/Hg □ 200mm/Hg	] 50mm/Hg  □ 75mm/Hg	j □ 100	Omm/Hg	□ 125mm/Hg	□ 150mm/Hg	□ 175mm/Hg
PICO:		5cmx20cm [ 5mx20cm [	15cmx30 15cmx30			
devices in (10cm) av to: Implarts.  The PICO7 radio frequency replace ba	ts, family, caregivers and the close proximity to fail, leading vay from other medical device that a cardioverter Defibrillator & PICO14 systems can be unuency interference that could atteries. If this this does not lar Next Day Home Delive	ng to serious hes that could lor (ICD), Pace sed in aircraft affect PICO7 correct the pr	narm includin be affected b emakers, Insi t, train and bo & PICO14 pe oblem, replace	g death. The Pico y magnetic interfeulin Pumps, Shunt pat transportation. rformance. If the te the device.	7 Pump must be pos rence. These includ Valves, Neurostimu During transport t	sitioned at least 4" e but are not limited lators or Cochlear here is a potential for
, _ ,	Ž	•				
	moist wound dressing tre				-	ntinued:
	etion or □ Primary dressing:_ ng changes:		Secondary	dressing	Dressing change	
rrequericy or dressi	ng changes.					
Name of Insti	tution					
Physician/Wo	ound Specialist:					
Signature:						
For HCCSS Use O	nly:					
•	form to Vendor Yurek's w Phone Number: 1-888-631-6			_	tion - via HPG.	

Thank you for your time and consideration